- About TapImmune
- News & Media
- Contact Us
Analysis of Phase I Trial indicates Safety and Positive Immune Response Data in 21 of 21 Patients Administered Folate Receptor Alpha Vaccine for Breast and Ovarian Cancers January 12, 2015, Seattle WA, TapImmune Inc. (OTCQB: TPIV) is extremely pleased to report the completion of data analysis...
Exercise in Full of Strategically Designed Warrant Package Would Result in $34,404,000 in Additional Funding Seattle, January 12, 2015 — TapImmune, Inc. (the “Company”), (otcqb:TPIV), today announced that it has entered into a definitive agreement with institutional investors for a...